Study on Docetaxel, Cabazitaxel, and Darolutamide for Men with Metastatic Castration-Resistant Prostate Cancer

2 1 1 1

What is this study about?

This clinical trial is focused on studying treatments for metastatic castration-resistant prostate cancer, a type of prostate cancer that continues to grow and spread even when the amount of testosterone in the body is reduced to very low levels. The study will explore the effectiveness of different treatment combinations involving the medications docetaxel, cabazitaxel, and darolutamide. Docetaxel and cabazitaxel are given as solutions for infusion, which means they are administered directly into the bloodstream through a vein, while darolutamide is taken orally in the form of film-coated tablets. Darolutamide is also known by its code names ODM-201 and BAY 1841788.

The purpose of the study is to compare how well patients do when treated with either docetaxel or cabazitaxel alone versus when these are combined with darolutamide. Participants will be randomly assigned to receive one of these treatment options. The study will monitor the participants over a period of time to see how long they can live without the cancer getting worse, which is known as progression-free survival. Other aspects being observed include overall survival, time to cancer progression, and any side effects experienced during the treatment.

The trial will last for up to 52 weeks, during which participants will receive regular check-ups and assessments to track their health and the cancer’s response to the treatment. The study aims to provide valuable information on the best treatment approach for men with this type of prostate cancer, potentially improving outcomes and quality of life for future patients. The study is expected to conclude in 2028.

1 joining the study

Upon joining the study, you will be randomly assigned to one of the treatment groups. This means you will receive either a combination of medications or a single medication, depending on the group you are placed in.

2 treatment with docetaxel or cabazitaxel

If you are assigned to receive docetaxel or cabazitaxel, these medications will be administered through an intravenous infusion. This means the medication will be given directly into your vein. The specific dosage and frequency will be determined by the study team based on your individual needs and the study protocol.

3 treatment with darolutamide

If you are in the group receiving darolutamide, you will take this medication orally in the form of film-coated tablets. The dosage is 300 mg, and the frequency and duration will be specified by the study team.

4 monitoring and assessments

Throughout the study, you will undergo regular monitoring and assessments to evaluate your health and the effectiveness of the treatment. This may include blood tests, imaging scans, and other evaluations as required by the study protocol.

5 end of treatment

At the end of the treatment period, you will have a final assessment to determine the outcome of the treatment. This will include a review of your health status and any changes in your condition.

6 follow-up

After completing the treatment, you may be asked to participate in follow-up visits to monitor your long-term health and any lasting effects of the treatment. The frequency and duration of these visits will be determined by the study team.

Who Can Join the Study?

Must be 18 years or older.
Must have a confirmed diagnosis of progressive metastatic castration-resistant prostate cancer (mCRPC). This means the cancer has spread and is not responding to treatments that lower testosterone.
Must show signs of cancer progression, which can be one of the following:
- Radiographic disease progression in soft tissue, meaning the cancer is growing as seen on imaging tests.
- Radiographic disease progression in bone, shown by at least two new bone lesions on a bone scan.
- PSA progression, which means an increase in prostate-specific antigen (PSA) levels, a marker used to track prostate cancer.
Must have had disease progression after treatment with at least one androgen receptor signaling inhibitor (ARSi), such as abiraterone, apalutamide, darolutamide, or enzalutamide.
Must have a WHO performance status of 2 or less, which is a measure of general well-being and ability to perform daily activities.
Must be able and willing to sign an Informed Consent Form before any study-related procedures.
Must have adequate blood, kidney, and liver function, as defined by specific medical tests:
- Hemoglobin level of at least 6.0 mmol/L.
- Platelet count of at least 100 x 10⁹/L.
- ALT/AST levels no more than 3 times the upper limit of normal, or 5 times if there are liver metastases.
- Creatinine clearance of at least 50 ml/min, which measures kidney function.
- Serum testosterone level of 1.7 nmol/L or less.

Who Cannot Join the Study?

Patients who do not have metastatic castration-resistant prostate cancer cannot participate. This is a type of prostate cancer that has spread to other parts of the body and does not respond to treatments that lower testosterone.
Only male patients can participate in this study.
Patients who are part of a vulnerable population cannot participate. This means people who might be at a higher risk of harm or exploitation, such as those with limited decision-making capacity.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Zuyderland Medisch Centrum Stichting	Geleen	The Netherlands
Frisius	Heerenveen	The Netherlands

Other Sites

Site Name	City	Country
Haga Hospital	Hague	The Netherlands
Isala Klinieken Stichting	Zwolle	The Netherlands
Jeroen Bosch Ziekenhuis Stichting	S-Hertogenbosch	The Netherlands
Canisius Wilhelmina Ziekenhuis	Nijmegen	The Netherlands
Albert Schweitzer Ziekenhuis	Dordrecht	The Netherlands
Ziekenhuisgroep Twente Stichting	Almelo	The Netherlands
Ziekenhuis Nij Smellinghe	Drachten	The Netherlands
Maasstad Ziekenhuis Stichting	Rotterdam	The Netherlands
St. Antonius Ziekenhuis	Nieuwegein	The Netherlands
Sint Franciscus Vlietland Groep Stichting	Rotterdam	The Netherlands
Deventer Ziekenhuis	Deventer	The Netherlands
Bravis Ziekenhuis	Roosendaal	The Netherlands
Gelre Hospitals	Zutphen	The Netherlands
Aqafqnlq Dm Rumtvu Zttbmeowzj Boiw	Goes	The Netherlands
Acevjndig Ulu	Amsterdam	The Netherlands
Ecuvzll Uoqstiydcuky Miejjif Chnevvc Rszqumisw (mnpzskz Mvh	Rotterdam	The Netherlands

Trial status

Country	Status	Recruitment Start
The Netherlands	Recruiting	29.11.2023

Trial locations

Investigated drugs:

Docetaxel is a type of chemotherapy drug used to treat various cancers, including prostate cancer. It works by stopping cancer cells from growing and dividing, which can help slow down or stop the progression of the disease.

Cabazitaxel is another chemotherapy medication used for treating prostate cancer, especially when other treatments have not been effective. Like docetaxel, it targets cancer cells and prevents them from multiplying, aiming to control the spread of the cancer.

Darolutamide is a medication used to treat prostate cancer by blocking the effects of male hormones that can promote the growth of cancer cells. It is often used in combination with other treatments to enhance their effectiveness in controlling the disease.

Investigated diseases:

Hormone-refractory prostate cancer

Metastatic Castration-Resistant Prostate Cancer – This is a type of prostate cancer that continues to grow and spread to other parts of the body despite treatments that lower testosterone levels. The disease progresses as cancer cells become resistant to hormonal therapy, which is initially used to control the growth of prostate cancer. Over time, the cancer may spread to bones, lymph nodes, or other organs, leading to various symptoms depending on the areas affected. As the disease advances, patients may experience increased pain, particularly in the bones, and other complications related to the spread of cancer. The progression of the disease is often monitored through imaging tests and blood tests that measure prostate-specific antigen (PSA) levels. The disease is characterized by its resistance to conventional hormone therapy, necessitating alternative treatment approaches.

Trial ID:

2024-516939-28-00

Protocol code:

DAROTAXEL

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on Docetaxel, Cabazitaxel, and Darolutamide for Men with Metastatic Castration-Resistant Prostate Cancer

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?